Edwards Lifesciences stock forecast
Edwards Lifesciences’ probability-weighted price is $73.78 in October 2027, $76.25 in October 2028, and $77.56 in October 2029; bear, base, and bull probabilities are 28%, 55%, and 17%. It hinges on turning TAVR leadership and TMTT adoption into durable growth before the valuation rerates.
Where could Edwards Lifesciences’ shares be by 2029?
The probability-weighted price is $73.78 in October 2027, a 15% loss including dividends. It is $76.25 in October 2028, a 12% loss. By October 2029, the weighted price reaches $77.56, still a 10% loss. Bear probability is 28%, while base probability is 55%. Bull probability is 17%.
At October 2029, the range runs from $48.69 to $117.42. Today’s price is $86.60. Because every scenario assumes no dividend, the returns come entirely from the share price.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 28% | 55.33 (-36%) | 52.89 (-39%) | 48.69 (-44%) |
| Base | 55% | 75.94 (-12%) | 78.34 (-10%) | 79.94 (-8%) |
| Bull | 17% | 97.20 (+12%) | 107.98 (+25%) | 117.42 (+36%) |
| Weighted | 100% | 73.78 (-15%) | 76.25 (-12%) | 77.56 (-10%) |
What this means. The weighted row is the average expected share price after giving each case more or less influence based on its probability.
What has to go right, and what could go wrong for Edwards Lifesciences?
The base follows the steady rise in adjusted earnings across the historical record, while 2026 guidance calls for strong sales growth and operating-margin expansion. The next-twelve-month EPS estimate also supports earnings near $2 billion. The model excludes the latest quarter’s deferred-tax allowance and impairment, plus the earlier disposal gain, because they are not recurring operating profit. The bear case assumes slower TAVR, limited TMTT scaling and cost pressure. The bull case requires stronger patient growth, broader TMTT adoption and more operating leverage.
The bear path combines weaker operations with valuation compression. TAVR growth slows, hospital capacity limits procedures, and TMTT remains concentrated in early centers. Legal, tax and launch costs restrict margin recovery. The path begins at $55.33 and ends at $48.69. Its probability is 28% because these risks are visible, although historical adjusted earnings growth makes sustained contraction less likely than the base case.
How much cash does Edwards Lifesciences really make?
Profit and cash differ because accounting records income when it is earned, while cash flow records when money arrives and leaves. Customers may pay after Edwards records a sale, and expenses such as depreciation or stock compensation may reduce profit without an immediate cash payment. Operating cash flow reached $1,595.2 million in 2025, helped by better operations and lower tax payments after the unusually heavy cash-tax burden associated with the 2024 Critical Care sale.
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| − Capital spending | 256.5 | 235.8 | 217.6 | 208.3 |
| − Stock pay | 157.9 | 145.6 | 124.8 | 113.6 |
What this means. Stock pay does not use cash today, but we subtract it because giving employees shares reduces existing investors’ ownership.
What does an investor pay for Edwards Lifesciences today?
| Today (Oct 18, 2026) | |
|---|---|
| Share price | 86.60 |
| Market value (calculated) | 49,916.2 |
| Enterprise value (calculated) | 46,262.2 |
| P/E, last 12 months (calculated) | 51.2x |
| P/E, next 12 months (calculated) | 25.5x |
| EV / revenue, last 12 months (calculated) | 7.1x |
What this means. The business value is lower than the stock-market value because it subtracts the company's cash and short-term investments.